Strategic Investment Advisors MI Has $1.19 Million Position in Pfizer Inc. (NYSE:PFE)

Strategic Investment Advisors MI cut its stake in shares of Pfizer Inc. (NYSE:PFE) by 45.4% in the 1st quarter, HoldingsChannel.com reports. The firm owned 46,998 shares of the biopharmaceutical company’s stock after selling 39,033 shares during the quarter. Strategic Investment Advisors MI’s holdings in Pfizer were worth $1,191,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Beam Wealth Advisors Inc. boosted its position in Pfizer by 1.5% during the fourth quarter. Beam Wealth Advisors Inc. now owns 27,444 shares of the biopharmaceutical company’s stock valued at $728,000 after purchasing an additional 401 shares during the last quarter. Providence Capital Advisors LLC boosted its position in Pfizer by 0.4% during the fourth quarter. Providence Capital Advisors LLC now owns 114,358 shares of the biopharmaceutical company’s stock valued at $3,034,000 after purchasing an additional 409 shares during the last quarter. Donaldson Capital Management LLC boosted its position in Pfizer by 1.2% during the fourth quarter. Donaldson Capital Management LLC now owns 35,694 shares of the biopharmaceutical company’s stock valued at $947,000 after purchasing an additional 410 shares during the last quarter. Noesis Capital Mangement Corp boosted its position in Pfizer by 2.6% during the fourth quarter. Noesis Capital Mangement Corp now owns 16,357 shares of the biopharmaceutical company’s stock valued at $434,000 after purchasing an additional 413 shares during the last quarter. Finally, First Command Advisory Services Inc. boosted its position in Pfizer by 2.5% during the fourth quarter. First Command Advisory Services Inc. now owns 17,479 shares of the biopharmaceutical company’s stock valued at $464,000 after purchasing an additional 418 shares during the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

PFE has been the subject of several recent research reports. Citigroup reissued a “neutral” rating on shares of Pfizer in a research report on Thursday, March 27th. Guggenheim reissued a “buy” rating on shares of Pfizer in a research report on Tuesday, March 18th. The Goldman Sachs Group restated a “neutral” rating and issued a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on Pfizer in a research note on Tuesday, April 22nd. They issued a “neutral” rating and a $24.00 price objective on the stock. Finally, UBS Group upped their price objective on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Stock Performance

NYSE:PFE opened at $24.31 on Wednesday. The stock has a market cap of $138.18 billion, a P/E ratio of 17.61, a PEG ratio of 0.87 and a beta of 0.57. The stock has a 50 day simple moving average of $23.33 and a 200 day simple moving average of $24.87. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The business had revenue of $13.72 billion during the quarter, compared to analysts’ expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm’s revenue for the quarter was down 7.8% compared to the same quarter last year. During the same period last year, the firm posted $0.82 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, June 13th. Investors of record on Friday, May 9th were issued a dividend of $0.43 per share. The ex-dividend date was Friday, May 9th. This represents a $1.72 annualized dividend and a yield of 7.08%. Pfizer’s payout ratio is currently 124.64%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.